G-CSF and G-CSF Biosimilars Market

Table Of Content

Executive Summary
1. Introduction
Market Introduction
1. Market Definition
2. Scope of the Study
3. Market Structure
Research Methodology
1. Primary Research
2. Research Methodology
3. Assumptions & Exclusions
4. Secondary Data Sources
Market Factor Analysis
1. Value Chain Analysis: G Csf And G Csf Biosimilars Market
2. Porters Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitution
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
Recent Trends Analysis
Impact of COVID-19 on G Csf And G Csf Biosimilars Market
1. Pre and Post Covid -19 Market Scenario Analysis
2. Market Recovery Timeline and Challenge
3. Measures Taken by Top Players
Regulatory Landscape
G Csf And G Csf Biosimilars Market, By Product Type
1. Introduction
  1. Market Size and Forecast, By Product Type
2. Filgrastim
  1. Market Size and Forecast, By Region
3. Pegfilgrastim
  1. Market Size and Forecast, By Region
4. Lenograstim
  1. Market Size and Forecast, By Region
5. Other G-CSFs
  1. Market Size and Forecast, By Region
G Csf And G Csf Biosimilars Market, By Application
1. Introduction
  1. Market Size and Forecast, By Application
2. Neutropenia Treatment
  1. Market Size and Forecast, By Region
  2. Chemotherapy-Induced Neutropenia
    1. Market Size and Forecast, By Region
  3. Bone Marrow Transplantation
    1. Market Size and Forecast, By Region
  4. Others
    1. Market Size and Forecast, By Region
  5. Stem Cell Transplantation
    1. Market Size and Forecast, By Region
3. Chronic and Autoimmune Diseases
  1. Market Size and Forecast, By Region
4. Other Applications
  1. Market Size and Forecast, By Region
G Csf And G Csf Biosimilars Market, By End-User
1. Introduction
  1. Market Size and Forecast, By End-User
2. Hospitals & Clinics
  1. Market Size and Forecast, By Region
3. Specialty Cancer Centers
  1. Market Size and Forecast, By Region
4. Research & Academic Institutes
  1. Market Size and Forecast, By Region
5. Others
  1. Market Size and Forecast, By Region
G Csf And G Csf Biosimilars Market, By Distribution Channel
1. Introduction
  1. Market Size and Forecast, By Distribution Channel
2. Hospital Pharmacies
  1. Market Size and Forecast, By Region
3. Retail Pharmacies
  1. Market Size and Forecast, By Region
4. Online Pharmacies
  1. Market Size and Forecast, By Region
5. Others
  1. Market Size and Forecast, By Region
Regional Overview
1. Introduction
  1. Market Size and Forecast
2. North America
  1. Market Size and Forecast
    1. By Product Type
      1. Filgrastim
      2. Pegfilgrastim
      3. Lenograstim
      4. Other G-CSFs
    2. By Application
      1. Neutropenia Treatment
      2. Chronic and Autoimmune Diseases
      3. Other Applications
    3. By End-User
      1. Hospitals & Clinics
      2. Specialty Cancer Centers
      3. Research & Academic Institutes
      4. Others
    4. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  2. U.S.
    1. By Product Type
      1. Filgrastim
      2. Pegfilgrastim
      3. Lenograstim
      4. Other G-CSFs
    2. By Application
      1. Neutropenia Treatment
      2. Chronic and Autoimmune Diseases
      3. Other Applications
    3. By End-User
      1. Hospitals & Clinics
      2. Specialty Cancer Centers
      3. Research & Academic Institutes
      4. Others
    4. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  3. Canada
3. Europe
  1. Market Size and Forecast
    1. By Product Type
      1. Filgrastim
      2. Pegfilgrastim
      3. Lenograstim
      4. Other G-CSFs
    2. By Application
      1. Neutropenia Treatment
      2. Chronic and Autoimmune Diseases
      3. Other Applications
    3. By End-User
      1. Hospitals & Clinics
      2. Specialty Cancer Centers
      3. Research & Academic Institutes
      4. Others
    4. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  2. U.K.
    1. By Product Type
      1. Filgrastim
      2. Pegfilgrastim
      3. Lenograstim
      4. Other G-CSFs
    2. By Application
      1. Neutropenia Treatment
      2. Chronic and Autoimmune Diseases
      3. Other Applications
    3. By End-User
      1. Hospitals & Clinics
      2. Specialty Cancer Centers
      3. Research & Academic Institutes
      4. Others
    4. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  3. Germany
  4. France
  5. Spain
  6. Italy
  7. Russia
  8. Nordic
  9. Benelux
  10. Rest of Europe
4. APAC
  1. Market Size and Forecast
    1. By Product Type
      1. Filgrastim
      2. Pegfilgrastim
      3. Lenograstim
      4. Other G-CSFs
    2. By Application
      1. Neutropenia Treatment
      2. Chronic and Autoimmune Diseases
      3. Other Applications
    3. By End-User
      1. Hospitals & Clinics
      2. Specialty Cancer Centers
      3. Research & Academic Institutes
      4. Others
    4. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  2. China
    1. By Product Type
      1. Filgrastim
      2. Pegfilgrastim
      3. Lenograstim
      4. Other G-CSFs
    2. By Application
      1. Neutropenia Treatment
      2. Chronic and Autoimmune Diseases
      3. Other Applications
    3. By End-User
      1. Hospitals & Clinics
      2. Specialty Cancer Centers
      3. Research & Academic Institutes
      4. Others
    4. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  3. Korea
  4. Japan
  5. India
  6. Australia
  7. Singapore
  8. Taiwan
  9. South East Asia
  10. Rest of Asia-Pacific
5. Middle East and Africa
  1. Market Size and Forecast
    1. By Product Type
      1. Filgrastim
      2. Pegfilgrastim
      3. Lenograstim
      4. Other G-CSFs
    2. By Application
      1. Neutropenia Treatment
      2. Chronic and Autoimmune Diseases
      3. Other Applications
    3. By End-User
      1. Hospitals & Clinics
      2. Specialty Cancer Centers
      3. Research & Academic Institutes
      4. Others
    4. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  2. UAE
    1. By Product Type
      1. Filgrastim
      2. Pegfilgrastim
      3. Lenograstim
      4. Other G-CSFs
    2. By Application
      1. Neutropenia Treatment
      2. Chronic and Autoimmune Diseases
      3. Other Applications
    3. By End-User
      1. Hospitals & Clinics
      2. Specialty Cancer Centers
      3. Research & Academic Institutes
      4. Others
    4. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  3. Turky
  4. Saudi Arabia
  5. South Africa
  6. Egypt
  7. Nigeria
  8. Rest of MEA
6. LATAM
  1. Market Size and Forecast
    1. By Product Type
      1. Filgrastim
      2. Pegfilgrastim
      3. Lenograstim
      4. Other G-CSFs
    2. By Application
      1. Neutropenia Treatment
      2. Chronic and Autoimmune Diseases
      3. Other Applications
    3. By End-User
      1. Hospitals & Clinics
      2. Specialty Cancer Centers
      3. Research & Academic Institutes
      4. Others
    4. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  2. Brazil
    1. By Product Type
      1. Filgrastim
      2. Pegfilgrastim
      3. Lenograstim
      4. Other G-CSFs
    2. By Application
      1. Neutropenia Treatment
      2. Chronic and Autoimmune Diseases
      3. Other Applications
    3. By End-User
      1. Hospitals & Clinics
      2. Specialty Cancer Centers
      3. Research & Academic Institutes
      4. Others
    4. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  3. Mexico
  4. Argentina
  5. Chile
  6. Colombia
  7. Rest of LATAM
Competitive Landscape, 2024
1. Introduction
2. G Csf And G Csf Biosimilars Market Share Analysis, 2024 (%)
  1. Market Share Analysis, 2024
  2. Competition Ranking, 2024
  3. Key Developments & Growth Strategies
    1. Merger & Acquisition
    2. Product Launch
    3. Expansion
  4. Consolidated SWOT Analysis of Key Players
Company Profile
1. Amgen Inc.
  1. Business Overview
  2. Financial Data
  3. Key Product Categories
  4. Recent Developments
2. Sandoz (a Novartis division)
3. Teva Pharmaceutical Industries Ltd.
4. Pfizer Inc.
5. Biocon Limited
6. Dr. Reddy's Laboratories Ltd.
7. Mylan N.V.
8. Intas Pharmaceuticals Ltd.
9. Apotex Inc.
10. Coherus BioSciences, Inc.
11. Stada Arzneimittel AG
12. Celltrion Inc.
13. Samsung Bioepis Co., Ltd.
14. Zydus Cadila
15. Others

	


A PHP Error was encountered

Severity: Warning
Message:  Undefined array key "list_tbl_fig"
Filename: reports/toc.php
Line Number: 79


	Backtrace:
	
		
	
		
	
		
			
			File: /var/www/html/application/views/frontend/reports/toc.php

			Line: 79

			Function: _error_handler			

		
	
		
	
		
	
		
			
			File: /var/www/html/application/controllers/Web.php

			Line: 215

			Function: view			

		
	
		
	
		
			
			File: /var/www/html/index.php

			Line: 316

			Function: require_once

Check Discount

Get Free Sample

Buy Now

Key Topics Covered

Market Factors (Including Drivers and Restraint)
Market Trends
Market Estimates and Forcasts
Competitive Analysis
Future Market Opportunities

G-CSF and G-CSF Biosimilars Market By Type (Blood Disorders, Oncology Diseases, Chronic And Autoimmune Diseases, Growth Hormone Deficiencies), By Application (Human Growth Hormone, Erythropoietin, Mon. . . . .

Table Of Content

A PHP Error was encountered